Serum amyloid A as a marker and mediator of acute coronary syndromes

Future Cardiology

Volumn 4, Issue 5, 2008, Pages 495-504

  Filep, János G ^a   El Kebir, Driss ^a  

^a MAISONNEUVE ROSEMONT HOSPITAL   (Canada)

Author keywords

Acute coronary artery disease; Arherosclerosis; Cardiovascular risk prediction; Endothelial cells; Inflammation; Leukocytes; Serum amyloid A

Indexed keywords

ADVANCED GLYCATION END PRODUCT RECEPTOR; ATORVASTATIN; CD36 ANTIGEN; CHOLESTEROL; CHOLESTEROL ACYLTRANSFERASE INHIBITOR; CYSTATIN C; FORMYLPEPTIDE RECEPTOR LIKE 1; LIPOSOME; LIPOXIN A; ROSIGLITAZONE; SERUM AMYLOID A;

ACUTE CORONARY SYNDROME; APOPTOSIS; CARDIOVASCULAR RISK; CELL TRANSPORT; CHOLESTEROL TRANSPORT; CORONARY ARTERY ATHEROSCLEROSIS; CORONARY ARTERY DISEASE; DISEASE ASSOCIATION; DISEASE MARKER; DRUG MEGADOSE; DRUG TARGETING; ENDOTHELIAL DYSFUNCTION; HEART INFARCTION; HOST RESISTANCE; HUMAN; INFLAMMATORY CELL; LEUKOCYTE ACTIVATION; NONHUMAN; OBESITY; PATHOPHYSIOLOGY; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; REVIEW; THROMBOSIS; UNSTABLE ANGINA PECTORIS; WEIGHT REDUCTION;

EID: 55249100527     PISSN: 14796678     EISSN: 17448298     Source Type: Journal    
DOI: 10.2217/14796678.4.5.495     Document Type: Review

References (109)

1. Ross R: Atherosclerosis as an inflammatory disease. N. Engl. J. Med. 340, 115-126 (1999).
2. Tsimikas S, Willerson JT, Ridker PM: C-reactive protein and other emerging blood biomarkers to optimize risk stratification of vulnerable patients. J. Am. Coll. Cardiol. 47, C19-C31 (2006).
3. Nicholls S, Hazen SL: Myeloperoxidase and cardiovascular disease. Arterioscler. Thromb. Vasc. Biol. 25, 1102-1111 (2005).
4. Liuzzo G, Biasucci LM, Gallimore RJ et al.: The prognostic value of C-reactive protein and serum amyloid A protein in severe unstable angina. N. Engl. J. Med. 331, 417-424 (1994).
5. Johnson BD, Kip KE, Marroquin OC et al.: Serum amyloid A as a predictor of coronary artery disease and cardiovascular outcome in women: the National Heart, Lung, and Blood Institute-sponsored Women's Ischemia Syndrome Evaluation (WISE). Circulation 109, 726-732 (2004).
6. Meek RL, Urieli-Shoval S, Benditt EP: Expression of apolipoprotein serum amyloid A mRNA in human atherosclerotic lesions and cultured vascular cells: implications for serum amyloid A function. Proc. Natl Acad. Sci. USA 91, 3186-3190 (1994).
7. Maier W, Altwegg LA, Corti R et al.: Inflammatory markers at the site of ruptured plaque in acute myocardial infarction: locally increased interleukin-6 and serum amyloid A but decreased C-reactive protein. Circulation 111, 1355-1361 (2005).
8. Steel DM, Sellar GC, Uhlar CM, Simon S, de Beer FC, Whitehead AS: A constitutively expressed serum amyloid A protein gene (SAA4) is closely linked to, and shares structural similarities with an acute-phase serum amyloid A protein gene (SAA2). Genomics 16, 447-454 (1993).
9. Malle E, de Beer FC: Human serum amyloid A (SAA) protein: a prominent acute-phase reactant for clinical practice. Eur. J. Clin. Invest. 26, 427-435 (1996).
10. Sipe J: Revised nomenclature for serum amyloid A (SAA). Nomenclature Committee of the International Society of Amyloidosis. Part 2 (Editorial). Amyloid 6, 67-70 (1999).
11. Fasshauer M, Klein J, Kralisch S et al.: Serum amyloid A3 expression is stimulated by dexamethasone and interleukin-6 in 3T3-L1 adipocytes. J. Endocrinol. 183, 561-567 (2004).
12. Han CY, Subramanian S, Chan CK et al.: Adipocyte-derived serum amyloid A3 and hyaluronan play a role in monocyte recruitment and adhesion. Diabetes 56, 2260-2273 (2007).
13. de Beer MC, Yuan T, Kindy MS, Asztalos BF, Roheim PS, de Beer FC: Characterization of constitutive human serum amyloid A proteins (SAA4) as an apolipoprotein. J. Lipid Res. 36, 526-534 (1995).
14. Gabay C, Kushner I: Acute-phase proteins and other systemic responses to inflammation. N. Engl. J. Med. 340, 448-454 (1999).
15. Poitou C, Viguerie N, Cancello R et al.: Serum amyloid A: production by human white adipocyte and regulation by obesity and nutrition. Diabetologia 48, 519-528, (2005).
16. Sjoholm K, Palming J, Olofsson LE et al.: A microarray search for genes predominantly expressed in human omental adipocytes: Adipose tissue as a major production site of serum amyloid A. J. Clin. Endocrinol. Metab. 90, 2233-2239 (2005).
17. Yang R-Z, Lee M-J, Hu H et al.: Acute-phase serum amyloid A: an inflammatory adipokine and potential link between obesity and its metabolic complications. PLOS Med. 3, e287 DOI:10.1371/ journal.pmed.0030287 (2006).
18. Meek RL, Urieli-Shoval S, Benditt EP: Expression apolipoprotein serum amyloid A mRNA in human atherosclerotic lesions and cultured vascular cells: implications for serum amyloid A function. Proc. Natl Acad. Sci. USA 91, 3186-3190 (1994).
19. Kumon Y, Suehiro T, Hashimoto K, Nakatani K, Sipe JD: Local expression of acute phase serum amyloid A mRNA in rheumatoid arthritis synovial tissue and cells. J. Rheumatol. 26, 785-790 (1999).
20. O'Hara R, Murphy EP, Whitehead AS, Fitzgerald O, Bresnihan B: Acute-phase serum amyloid A production by rheumatoid arthritis synovial tissue. Arthritis Res. 2, 142-144 (2000).
21. Jensen LE, Whitehead AS: Regulation of serum amyloid A protein expression during the acute-phase response. Biochem. J. 334, 785-790 (1998).
22. Urieli-Shoval S, Linke RP, Matzner Y: Expression and function of serum amyloid A, a major acute-phase protein, in normal and disease states. Curr. Opin. Hematol. 7, 64-69 (2000).
23. Ray A, Kumar D, Ray P, Ray BK: Transcriptional activity of serum amyloid A-activating factor-1 is regulated by distinct functional modules. J. Biol, Chem. 279, 54637-54646 (2004).
24. Hagihara K, Nishikawa T Sugamata Y et al.: Essential role of STAT3 in cytokine-driven NF-κB-mediated serum amyloid A gene expression. Genes Cells 10, 1051-1063 (2005).
25. Hosai H, Webb NR, Glick JM et al.: Expression of serum amyloid A protein in the absence of the acute phase response does not reduce HDL cholesterol or apoA-1 levels in human apoA-I transgenic mice. J. Lipid Res. 40, 648-653 (1999).
26. Bausserman LL, Herbert PN, Rodger R, Nicolosi RJ: Rapid clearance of serum amyloid A from high-density lipoprotems. Biochim. Biophys. Acta 792, 186-191 (1984).
27. Coetzee GA, Stachan AF, van der Westhuyzen DR, Hopee HC, Jeenah M S, de Beer FC: Serum amyloid A-containing human high density lipoprotein 3: density, size, and apolipoprotein composition. J. Biol. Chem. 261, 9644-9651 (1986).
28. Hu W. Abe-Dohmae S, Tsujita M et al.: Biogenesis of HDL by SAA is dependent on ABCA1 in the liver in vivo. J. Lipid Res. 49, 386-393 (2008).
29. Lewis KE, Kirk EA, McDonald TO et al.: Increase in serum amyloid A evoked by dietary cholesterol is associated with increased atherosclerosis in mice. Circulation 110, 540-545 (2004).
30. Tannock LR, O'Brien KD, Knopp RH et al.: Cholesterol feeding increases C-reactive protein and serum amyloid A levels in lean insulin-sensitive subjects. Circulation 111, 3058-3062 (2005).
31. Cunnane G, Grehan S, Geoghegan S et al.: Serum amyloid A in the assessment of early inflammatory arthritis. J. Rheumatol, 27, 58-63 (2000)
32. Hartman A, Eide T, Fauchald P et al.: Serum amyloid A protein is a clinically useful indicator of acute renal allograft rejection. Nephrol. Dial. Transplantation 12, 161-167 (1997).
33. Erren M, Reinecke H, Junker R et al.: Systemic inflammatory parameters in patients with atherosclerosis of the coronary and peripheral arteries. Arterioscler. Thromb. Vasc. Biol. 19, 2355-2363 (1999).
34. Ridker PM, Hennekens CH, Buring JE, Rifai N: C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. N. Engl, J. Med. 342, 836-843 (2000).
35. Riedker PM, Rifai N, Pfeffer MA et al.: Inflammation, pravastatin, and the risk of coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events (CARE) Investigators. Circulation 98, 839-844 (1998).
36. Jousilahti P, Salomaa V, Rasi V, Valitera E, Palosuo T. The association of C-reactive protein, serum amyloid A and fibrinogen with prevalent coronary heart disease-baseline findings of the PAIS project. Atherosclerosis 156, 451-456 (2001).
37. Schillinger M, Exner M, Mlekusch W et al.: Inflammation and Carotid Artery-Risk for Atherosclerosis Study (ICARAS). Circulation 111, 2203-2209 (2005).
38. Fyfe Al, Rothenberg LS, de Beer FC, Cantor RM, Rotter JI, Lusis AJ: Association between serum amyloid A proteinsand coronary artery disease: evidence from two distinct arteriosclerotic processes. Circulation 96, 2914-2919 (1997).
39. Kip KE, Marroquin OC, Shaw LJ et al.: Global inflammation predicts cardiovascular risk in women: a report from the Women's Ischemia Syndrome Evaluation (WISE) study. Am. Heart J. 150, 900-906 (2005).
40. Leinonen E, Hurt-Carrejo E, Wildund O, Hulten LM, Hiukka A, Taskinen MR: Insulin resistance and adiposity correlate with acute-phase reaction and soluble cell adhesion molecules in Type 2 diabetes. Atherosclerosis 166, 387-394 (2003).
41. Ebeling PA, Teppo M, Koistinen HA et al.: Troglitazone reduces hyperglycemia and selectively acute-phase proteins in patients with Type II diabetes. Diabetologia 42, 1433-1438 (1999).
42. Wong M, Toh L, Wilson A et al.: Reduced arterial elasticity in rheumatoid arthritis and the relationship to vascular disease risk factors and inflammation. Arthritis Rheum. 48, 81-89 (2003).
43. Shah C, Hari-Dass R, Raynes JG: Serum amyloid A is an innate immune opsonin for Gram-negative bacteria. Blood 108, 1751-1757(2006).
44. Badolato R, Wang JM, Stornello S-L, Ponzi AN, Duse M, Musso T. Serum amyloid A is an activator of PMN antimicrobial functions: induction of degranulation, phagocytosis, and enhancement of anti-Candida activity. J. Leukoc. Biol. 67, 381-386 (2000).
45. Yamada T, Kakihara T, Kamishima T, Fukuda T, Kawai T: Both acute phase and constitutive serum amyloid A are present in atherosclerotic lesions. Pathol. Int. 46, 797-800 (1996).
46. Badolato R, Wang JM, Murphy WJ et al.: Serum amyloid A is a chemoattractant: Induction of migration, adhesion, and tissue infiltration of monocytes and polymorphonuclear leukocytes. J. Exp. Med. 180, 203-209 (1994).
47. Xu L, Badolato R, Murphy WJ et al.: A novel biologic function of serum amyloid A. Induction of T lymphocyte migration and adhesion. J. Immunol. 155, 1184-1190 (1995).
48. Mullan RH, Bresnihan B, Golden-Mason L et al.: Acute-phase serum amyloid A stimulation of angiogenesis, leukocyte recruitment, and matrix degradation in rheumatoid arthritis through an NF-κB-dependent signal transduction pathway. Arthritis Rheum. 54, 105-114 (2006).
49. Migira K, Kawabe Y, Tominaga M, Origuchi T, Aoyagi T, Eguchi K: Serum amyloid, A protein induces production of matrix metalloproteinases by human synovial fibroblasts. Lab. Invest. 78, 535-539 (1998).
50. Strissel KJ, Girard MT, West-Mays JA et al.: Role of serum amyloid A as an intermediate in the IL-I and PMA-stimulated signaling pathways regulating expression of rabbit fibroblast collagenase. Exp. Cell Res. 237, 275-287 (1997).
51. Artl A, Marsche G, Lestavel S, Sattler W, Malle E: Role of serum amyloid during metabolism of acute-phase HDL by macrophages. Arterioscler. Thromb. Vasc. Biol. 20, 763-772 (2000).
52. Liang J, Schreiber B, Salmona M et al.: Amino terminal region of acute phase, but not constitutive, serum amyloid A (apoSAA) specifically binds and transports cholesterol into aortic smooth muscle and HepG2 cells. J. Lipid Res. 37, 2109-2116 (1996).
53. Chait A, Han CY, Oram JF, Heinecke JW: Lipoprotein-associated inflammatory proteins: markers or mediators of cardiovascular diseases? J. Lipid Res. 46, 389-403 (2005).
54. Banka CL, Yuan T, de Beer MC, Kindy, M, Curtiss LK, de Beer FC: Serum amyloid A (SAA): influence on HDL-mediated cellular cholesterol efflux. J. Lipid Res. 36, 1058-1065 (1995).
55. Tam SP, Flexman A, Hulme J, Kisilevsky R: Promoting export of macrophage cholesterol: die physiological role ofa major acute-phase protein, serum amyloid A 2.1. J. Lipid Res. 43, 1410-1420 (2002).
56. Stonik JA, Remaley AT, Demosky SJ, Neufeld EB, Bocharov A, Brewer HB: Serum amyloid A promotes ABCA1-dependent and ABCA1-independent lipid efflux from cells. Biochem. Biophys. Res. Commun. 321, 936-941 (2004).
57. Getz GS, Reardon CA. SAA, HDL biogenesis, and inflammation. J. Lipid Res. 49, 386-393 (2008).
58. O'Brien KD, McDonald TO, Kunjathoor V et al.: Serum amyloid A and lipoprotein retention in murine models of atherosclerosis. Arterioscler. Thromb. Vasc. Biol. 25, 785-790 (2005).
59. Husebekk A, Skogen B, Husby G: Characterization of amyloid proteins AA and SAA as apolipoproteins of high density lipoprotein (HDL). Displacement of SAA from the HDL-SAA complex by ApoAl and apoAII. Scand. J. Immunol. 25, 375-381 (1987).
60. Van Lenten BJ, Hama SY, de Beer FC et al.: Anti-inflammatoryt HDL becomes pro-inflammatory during the acute-phase response. Loss of protective effect of HDL against LDL oxidation in aortic wall cell cocultures. J. Clin. Invest. 96, 2758-2767 (1995).
61. Wu A, Hinds CJ, Thiemermann C: High-density lipoproteins in sepsis and septic shock: Metabolism, actions, and therapeutic applications. Shock 21, 210-221 (2004).
62. van der Wal AC, Becker AE, van der Loos CM et al.: Site of intimal rupture or erosion of thrombosed coronary atherosclerotic plaques is characterized by an inflammatory process irrespective of the dominant plaque morphology. Circulation 89, 36-44 (1994).
63. Libby P: Inflammation in atherosclerosis. Nature 420, 868-874 (2002).
64. Schechter AD, Giesen PL, Taby O et al.: Tissue factor expression in human arterial smooth muscle cells: TF is present in three cellular pools after growth factor stimulation. J. Clin. Invest. 100, 2276-2285 (1997).
65. Buffon A, Biasucci LM, Liuzzo G, D'Onofrio G, Crea F, Maseri A: Widespread coronary inflammation in unstable angina. N. Engl. J. Med. 347, 5-12 (2002).
66. Baldus S, Heeschen C, Meinertz T et al.: Myeloperoxidase serum levels predict risk in patients with acute coronary syndromes. Circulation 108, 1440-1445 (2003).
67. Garlichs CD, Eskafi S, Cicha I et al.: Delay of neutrophil apoptosis in acute coronary syndromes. J. Leukoc. Biol. 75, 828-835 (2004).
68. Naruko T, Ueda M, Haze K et al.: Neutrophil infiltration ofculprit lesions in acute coronary syndromes. Circulation 106, 2894-2900 (2002).
69. Van Lenten BJ, Wagner AC, Navab M et al.: Lipoprotein inflammatory properties and serum amyloid A levels but not cholesterol levels predict lesion area in cholesterol-fed rabbits. J. Lipid Res. 48, 2344-2353 (2007).
70. He RL, Zhou J, Hanson C, Chen J, Ye RD: The acute-phase protein serum amyloid A induces G-CSF expression and, granulocytosis (Abstract). J. Leukoc. Biol. Suppl. 44-45 (2007).
71. Su SB, Gong W, Gao JL et al.: A seven-transmembrane, G-protein-coupled receptor, FPRL 1, mediates the chemotactic activity of serum amyloid A for human phagocytic cells. J. Exp. Med. 189, 395-402 (1999).
72. 4R. Blood 101, 1572-1581 (2003).
73. Furlaneto CJ, Cam pa A: A novel function of serum amyloid A: a Potent stimulus for the release of tumor necrosis factor-α, interleukin-1β, and interleukin-8 by human blood neutrophil. Biochem. Biophys. Res. Commun. 268, 405-408 (2000).
74. Vallon R, Freuler F, Desta-Tsedu N et al.: Serum amyloid A (apoSAA) expression is up-regulated in rheumatoid arthritis and induces transcription of matrix metalloproteinases. J. Immunol. 166, 2801-2807 (2001).
75. Patel H, Fellowes R. Coade S, Woo P: Human serum amyloid A has cytokine-like properties. Scand. J. Immunol. 48, 410-418 (1998).
76. El Kebir D, József L, Pan W, Petasis NA, Serhan CN, Filep JG: Aspirin-triggered lipoxins override the apoptosis-delaying action of serum amyloid A in human neutrophils: a novel mechanism for resolution of inflammation. J. Immunol. 179, 616-622 (2007).
77. Christenson K, Björkman L, T-dsangemo C, Bylund J: Serum amyloid A inhibits apoptosis of human neutrophils via a P2X7-sensitive pathway indepedent of formyl peptide receptor-like 1, J Leukoc. Biol. 83, 139-148 (2008).
78. Colotta F, Re F, Polentarutti N, Sozzani S, Mantovani A: Modulation of granulocyte survival and programmed cell death by cytokines and bacterial products. Blood 80, 2012-2020 (1992).
79. Khreiss T, József L, Hossain S, Chan JSD, Potempa LA, Filep JG: Loss of pentameric symmetry of C-reactive protein is associated with delayed apoptosis of human neutrophils. J. Biol, Chem. 277, 40775-40781 (2002).
80. Zhao Y, Zhou S, Heng CK: Impact of serum amyloid A on tissue factor and tissue factor pathway inhibitor expression and activity in endothelial cells. Arterioscler. Thromb. Vasc. Biol. 27, 1645-1650 (2007).
81. Cai H, Song C, Endoh I et al.: Serum amyloid A induces monocyte tissue factor. J. Immunol. 178, 1852-1860 (2007).
82. Song C, Shen Y, Yamen E et al.: Serum amyloid A may potentiate prothrombotic and proinflammatory events in acute coronary syndromes. Atherosclerosis DOI: 10.1016/j.atherosclerosis.2008.04.09 (2008) (Epub ahead of print.).
83. Zimlichman S, Danon A, Nathan I, Mozes G, Shainkin-Kestenbaum R. Serum amyloid A, an acute phase protein, inhibits platelet activation. J. Lab. Clin. Med. 116, 180-186 (1990).
84. Urieli-Shoval S, Shubinsky G, Linke RP Fridkin M, Tabi I, Marzner Y: Adhesion of human platelets to serum amyloid A. Blood 99, 1224-1229 (2002).
85. Polgar J, Matuskova J, Wagner DD: The P-selectin, tissue factor, coagulation triad. J. Thromb. Haemost. 3, 1590-1596 (2005).
86. Migita K, Yamasaki S, Shibatomi K et al.: Impaired degradation of serum amyloid A (SAA) protein by cytokine-stimulated monocytes. Clin. Exp. Immunol. 123, 408-411 (2001).
87. Cai I, de Beer MC, de Beer FC, van der Westhuyzen DR. Serum amyloid A is a ligand for scavenger receptor class B type I and inhibits high density lipoprotein binding and selective lipid uptake. J. Biol. Chem. 280, 2954-2961 (2005).
88. Baranova IN, Vishnyakova TG, Bocharov AV et al.: Serum amyloid A binding to CLA-I (CD36 and LIMPII analogous-1) mediates serum amyloid A protein-induced activation of ERK1/2 and p38 mitogen-activated protein kinases. J. Biol. Chem. 280, 8031-8040 (2005).
89. Sandri S, Rodriguez D, Gomes E et al.: Is serum amyloid A an endogenous TLR4 agonist? J. Leukoc. Biol. 83, 1174-1180 (2008).
90. Chiang N, Serhan CN, Dahlen SE et al.: The lipoxin receptor ALX: Potent ligand-specific and stereoselective actions in vivo. Pharmacol. Rev. 58, 463-487 (2006).
91. Perretti M, Chiang N, La M et al.: Endogenous lipid- and pepride-derived anti-inflammatory pathways generated with glucocorticoid and aspirin treatment activate the lipoxin A4 receptor. Nat. Med. 8, 1296-1302 (2002).
92. Le Y, Gong W, Tiffany HL et al.: Amyloid β42 activates a G-protein-coupled chemoattractant receptor, FPR-like-1. J Neurosci. 21, RC123 (2001).
93. Lee HY, Kim MK, Park KS et al.: Serum amyloid A stimulates matrix metalloproteinase-9 upregulation via firmly peptide receptor like-1-mediated signaling in human monocytic cells. Biochem. Biophys. Res. Commun. 330, 989-998 (2005).
94. Bae YS, Lee HY, Jo EJ et al.: Identification of peptides that antagonize formyl peptide receptor-like 1-mediated signaling. J Immunol. 173, 607-614 (2004).
95. Gu BJ, Zhang WY, Bendall LJ, Chessell IP. Buell GN, Wiley JS: Expression of P2X7 purinoceptors on human lymphocytes and monocytes: evidence for nonfucntional P2X7 receptors. Am. J. Physiol. Cell Physiol. 279, C1189-C1197 (2001).
96. Beigi RD, Kertesy SB, Aquilina G, Dubyak CR: Oxidized ATP (oATP) attenuates proinflammatory signaling via P2 receptor-independent mechanisms. Br. J. Pharmacol. 140, 507-519 (2003).
97. Björkman L, Karlsson J, Karisson A et at.: Serum amyloid A mediates human neutrophil production of reactive oxygen species through a receptor independent of formyl peptide receptor like-1. J. Leukoc. Biol. 83, 245-253 (2008).
98. Hatanaka E, Costa Carvalho BT, Condino-Neto A, Campa A: Hyperresponsiveness of neutrophils from gp9lphox-deficient patients to lipopolysaccharide and serum amyloid A. Immunol Lett. 94, 43-46 (2004).
99. Cheng N, He R, Tian J, Ye PP, Ye RD: Cutting edge: TLR2 is a functional receptor for acute-phase serum amyloid A. J. Immunol. 181, 22-26 (2008).
100. O'Brien KD, Brehm BJ, Seeley RJ et al.: Diet-induced weight loss is associated with decreases in plasma serum amyloid A and C-reactive protein independent of dietary macronutrient composition in obese subjects. J. Clin. Endocrinol. Metab. 90, 2244-2249 (2005).
101. Kinlay S, Schwartz GG, Olsson AG et al.: High-dose atorvastatin enhances the decline in inflammatory markers in patients with acute coronary syndrome in the MIRACL Study. Circulation 108, 1560-1566 (2003).
102. Bokarewa M, Abrahamson M, Levshin N et al.: Cystatin C binds serum amyloid A, downregulating its cytokine-generating properties. J. Rheumatol. 34, 1293-1301 (2007).
103. Serhan CN, Maddox JF, Petasis NA et al.: Design of lipoxin A4 stable analogs that block transmigration and adhesion of human neutrophils. Biochemistry 34, 14609-14615 (1995).
104. Claria J, Serhan CN: Aspirin triggers previously undescribed bioactive eicosanoids by human endothelial cell-leukocyte interactions. Proc. Natl. Acad Sci. USA 92, 9475-9479 (1995).
105. Birnbaum Y, Ye Y, Lin Y et al.: Augmentation of myocardial production of 15-epi-lipoxin A4 by pioglitazone and atorvastarin in the rat. Circulation 114, 929-935 (2006).
106. Bonnans C, Vachier I, Chavis C, Godard P, Bousquet J, Chanez P: Lipoxins are potential endogenous antiinflammatory mediators in asthma. Am. J. Respir. Crit. Care Med 165, 1531-1535 (2002).
107. Chiang N, Bermudez EA, Ridker PM, Hurwitz S, Serhan CN: Aspirin triggers anti-inflammatory 15-epi-lipoxin A4 and inhibits thromboxane in a randomized human trial. Proc. Natl. Acad. Sci. USA 101, 15178-15183 (2004).
108. Kisilevsky R, Tam SP: Macrophage cholesterol efflux and the active domains of serum amyloid A2.1. J. Lipid Res. 44, 2257-2269 (2003).
109. -/-mice. J. Lipid Res. 46, 2091-2101 (2005).